Critical Advances in the Management of Immune Thrombocytopenic Purpura
Pathophysiology of ITP
Initial Management of ITP
Splenectomy in Patients With ITP Who Relapse on Steroids
Acute Intervention in ITP
Therapeutic Options in Refractory ITP
|
 1 |
May 23, 2010 |
Practice-Changing Developments in Hematologic Malignancies
Rapid Reviews in Oncology
Frontline Therapy for MM
Emerging Agents for CLL
Treatment Options for MDS
Optimization of Therapy for NHL
Advances in TCL
|
1 |
Apr 30, 2010 |
New Developments in Endocrine Therapy and Bone-Targeted Agents for Breast Cancer
Cancer Summaries & Commentaries Vol. 2, No. 1
Up-Front Letrozole vs. Tamoxifen Alone or in Sequence: BIG I-98 Trial
Up-Front Exemestane vs. Tamoxifen: TEAM Trial
Zoledronic Acid for Letrozole-Associated Bone Loss: ZO-FAST Trial
Risedronate for Anastrozole-Associated Bone Loss: SABRE Trial
First-line Letrozole With or Without Lapatinib: EGF30008 Trial
Low-Dose vs. High-Dose Estradiol in AI-Resistant Advanced Breast Cancer
|
1 |
Apr 1, 2010 |
New Developments in Targeted Therapy for Gastrointestinal Stromal Tumors
Oncology Briefings Vol. 7, No. 1
Targeted Therapy for GIST
|
0.5 |
Mar 31, 2010 |
Efficacy and Safety Considerations in the Treatment of a Patient With HER2-Positive Early-Stage Breast Cancer
Oncology Consultations Vol. 5, No. 3
Efficacy and Safety in HER2+ Early-Stage Breast Cancer
|
1 |
Mar 17, 2010 |
Defining New Therapeutic Options for Chronic Lymphocytic Leukemia
Online Only Cancer Summaries & Commentaries Vol. 2, No. 2
MoAbs in CLL
FC Compared to FCR in CLL: Results From 2 Phase III Trials
Ofatumumab in Refractory CLL
Subcutaneous Alemtuzumab in Fludarabine-Refractory CLL
Trials of MoAbs in Relapsed/Refractory CLL
|
1 |
Mar 10, 2010 |
|
Oncology Briefings Vol. 6, No. 11
Inhibitors of the mTOR and VEGF Pathways in RCC
|
0.5 |
Dec 31, 2009 |
Monographs in Renal Cell Carcinoma Vol. 3, No. 1
Antiangiogenic Therapy in RCC
mTOR Inhibitors in Metastatic RCC
|
1 |
Dec 30, 2009 |
|
Oncology Briefings Vol. 6, No. 9
Targeted Agents in Advanced Thyroid Cancer
|
0.5 |
Dec 18, 2009 |
|
Case Studies in Breast Cancer Vol. 6, No. 9
Adjuvant AI Therapy in Hormone Receptor–Positive Breast Cancer
|
1 |
Dec 17, 2009 |
Cancer Summaries & Commentaries Vol. 1, No. 5
Docetaxel Plus Placebo or Bevacizumab in Locally Recurrent/Metastatic Breast Cancer
Docetaxel/Epirubicin vs. Docetaxel/Capecitabine in LABC/MBC
Trastuzumab/Pertuzumab in Patients With HER2-Positive MBC
First-line Lapatinib/Pazopanib in HER2-Positive LABC/MBC
Lapatinib/Bevacizumab in HER2-Positive MBC
Nomogram to Predict Brain Metastasis in MBC
|
1 |
Dec 17, 2009 |
|
Case Studies in Breast Cancer Vol. 6, No. 8
Bone Health in a Postmenopausal Patient With HR+ Early-Stage Breast Cancer
|
1 |
Dec 11, 2009 |
|
Oncology Briefings Vol. 6, No. 8
EndothelinA Receptor Antagonists in Prostate Cancer
|
0.5 |
Nov 25, 2009 |
|
Oncology Briefings
VEGF/VEGFR Agents in Advanced/Persistent Ovarian Cancer
|
0.5 |
Nov 25, 2009 |
Biological Therapy of Breast Cancer Vol. 9, No. 2
Next Generation of Targeted Therapies in Breast Cancer
Are Anthracyclines Still Needed?
|
1 |
Nov 25, 2009 |
|
Oncology Consultations Vol. 5, No. 2
Treatment of a Never-Smoker With NSCLC
|
1 |
Nov 21, 2009 |
From Signal Transduction to Epigenetic Regulation of Gene Expression in Oncology: Challenging Clinical Cases
Improving Outcomes for Patients With CML
Practical Issues in the Management of CLL
Targeting Epigenetics in Cancer
Emerging HDACI Combinations in Solid Tumors
Roundtable Discussion
|
1 |
Nov 20, 2009 |
|
Case Studies in Oncology Vol. 9, No. 2
Treatment for Metastatic Pancreatic Cancer
|
1 |
Nov 18, 2009 |
|
Oncology Briefings Vol. 6, No. 7
Optimizing mTOR and VEGF Inhibitors in Advanced RCC
|
0.5 |
Nov 17, 2009 |
|
Case Studies in Breast Cancer Vol. 6, No. 7
Bone Health in Hormone Receptor–Negative Early-Stage Breast Cancer
|
1 |
Nov 13, 2009 |
|
Case Studies in Breast Cancer Vol. 6, No. 6
Adjuvant Therapy for a Patient With HER2+ Breast Cancer and Borderline LVEF
|
1 |
Nov 12, 2009 |
Refining and Personalizing Treatment for Non–Small-Cell Lung Cancer
Current Approaches With EGFR Inhibitors in NCSLC
Approaches to Inhibit Angiogenesis: Targeting the Ligand
Small-Molecule VEGFR TKIs
Class-Effect Toxicities With Antiangiogenic Agents
Moving Toward Individualized Cancer Therapy for NSCLC
|
1 |
Nov 3, 2009 |
|
Case Studies in Oncology Vol. 9, No. 3
GBM: Advances and Challenges
|
1 |
Oct 31, 2009 |
|
Cancer Summaries & Commentaries Vol. 1, No. 4
Targeted Strategies for Metastatic and Locally Advanced NSCLC
|
1 |
Oct 31, 2009 |
Expanding Options for the Treatment of Metastatic Breast Cancer
Novel Inhibitors of HER2
Combination Chemotherapy in MBC
First-line Therapy for Aggressive Metastatic Disease
Angiogenesis: VEGF- and VEGFR-Targeted Therapies
|
1 |
Oct 29, 2009 |
Advances in Lung Cancer Vol. 8, No. 1
Targeted Agents in Early-Stage and Locally Advanced NSCLC
Safety of Antiangiogenic Agents in Advanced NSCLC
Optimizing Chemotherapy in Resectable NSCLC
|
1 |
Oct 27, 2009 |
New Therapeutic Options for Challenging Hematologic Diseases
Clinical Value of IPSS Risk Assessment
Extending Outcomes in MDS
Patient With AML in First Complete Remission
Management of a 28-Year-Old Patient With PNH
|
1 |
Oct 17, 2009 |
Chronic Lymphocytic Leukemia: The Cutting Edge Vol. 13, No. 2
2008 Oncology Conference Highlights
Genomic Profiling Identifies CLL Subtypes
MRD Negativity and Consolidation Therapy in CLL
|
1 |
Oct 17, 2009 |
|
Case Studies in Breast Cancer Vol. 6, No. 5
HER2+ Breast Cancer Progressing After Adjuvant Therapy
|
1 |
Sep 29, 2009 |
|
Case Studies in Pain Management Vol. 2, No. 2
Nociceptive and Neuropathic Pain Management
|
1 |
Sep 29, 2009 |
In-Depth Tumor Board: Biologic Therapy for Breast Cancer
Anti-HER2 Therapy for Node-Negative Breast Cancer
Cardiotoxicity and Anti-HER2 Therapy
Refractory HER2+ MBC
Antiangiogenic Therapy for MBC
Chemotherapy Options for MBC
|
1 |
Sep 24, 2009 |
|
Case Studies in Oncology Vol. 9, No. 1
Gemcitabine-Refractory Pancreatic Cancer
|
1 |
Sep 24, 2009 |
|
Case Studies in Breast Cancer Vol. 6, No. 3
Neoadjuvant Treatment of HER2+ IBC
|
1 |
Sep 12, 2009 |
Biological Therapy of Breast Cancer Vol. 9, No. 1
Antiangiogenic Agents in Breast Cancer
Combining Targeted Agents in Breast Cancer
Molecular Aberrations in Breast Cancer and Future Therapy
|
1 |
Sep 12, 2009 |
|
Case Studies in Breast Cancer Vol. 6, No. 4
Late-Extended Treatment of Breast Cancer With an AI
|
1 |
Sep 10, 2009 |
|
Oncology Briefings Vol. 6, No. 5
Optimizing the Chemotherapy Backbone in Metastatic NSCLC
|
0.5 |
Sep 2, 2009 |
Receptor-Based Therapeutics: An Interactive Exposé
Personalized Cancer Therapy
Options for ErbB2-Positive MBC That Has Progressed on ErbB2-Targeted MoAb Therapy
Antiangiogenic Therapy in Newly Diagnosed MBC
|
1 |
Aug 27, 2009 |
Cancer Summaries & Commentaries Vol. 1, No. 2
Broadening the Horizon of Targeted Agents in Advanced Non–Small-Cell Lung Cancer
Safety of Bevacizumab in Advanced NSCLC With Treated or Untreated CNS Metastases
Pemetrexed/Carboplatin Plus Bevacizumab in Advanced Nonsquamous NSCLC
Paclitaxel/Carboplatin With or Without CP-751871 as First-line Therapy for Advanced NSCLC
rhApo2L/TRAIL Plus Paclitaxel/Cisplatin/Bevacizumab in Advanced Nonsquamous NSCLC
XL647 in Patients With NSCLC and Acquired Resistance to Gefitinib or Erlotinib
|
1 |
Aug 26, 2009 |
The Next Generation of Combinations for Breast Cancer: Building on Targeted Therapies
Online Only Cancer Summaries & Commentaries
Dual HER1/HER2 Inhibition in Refractory MBC
Every-3-Week Trastuzumab-MCC-DM1 in HER2+ MBC
Everolimus/Paclitaxel/Trastuzumab in Trastuzumab-Resistant HER2+ MBC
Neoadjuvant Letrozole/Everolimus in ER+ Breast Cancer
Vorinostat/Tamoxifen in AI-Resistant ER+ MBC
|
1 |
Aug 22, 2009 |
|
Case Studies in Breast Cancer Vol. 6, No. 2
First-line Treatment of HER2– MBC
|
1 |
Aug 20, 2009 |
|
Cancer Summaries and Commentaries Vol. 1, No. 1
Bevacizumab/Docetaxel in Advanced Breast Cancer
Lapatinib With or Without Pazopanib in HER2-Positive MBC
Trastuzumab/Pertuzumab for MBC That Had Progressed on Prior Trastuzumab
Tanespimycin/Trastuzumab in HER2-Positive MBC That Had Progressed on Prior Trastuzumab
Anastrozole/Gefitinib in Postmenopausal Women With Hormone Receptor–Positive MBC
Cetuximab With or Without Carboplatin for Triple-Negative MBC
|
1 |
Aug 20, 2009 |
|
Case Studies in Colorectal Cancer Vol. 4, No. 1
Extended Biologic Treatment of a Patient With Metastatic Colorectal Cancer
|
1 |
Jul 15, 2009 |
